Trade Olema Pharmaceuticals, Inc. - OLMA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.25 |
| Open | 5.26 |
| 1-Year Change | -49.37% |
| Day's Range | 5.26 - 5.68 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 2, 2025 | 5.58 | 0.36 | 6.90% | 5.22 | 5.69 | 5.22 |
| May 1, 2025 | 5.25 | 0.20 | 3.96% | 5.05 | 5.27 | 4.98 |
| Apr 30, 2025 | 5.11 | 0.25 | 5.14% | 4.86 | 5.20 | 4.86 |
| Apr 29, 2025 | 4.99 | 0.26 | 5.50% | 4.73 | 5.10 | 4.73 |
| Apr 28, 2025 | 4.84 | -0.03 | -0.62% | 4.87 | 5.00 | 4.62 |
| Apr 25, 2025 | 4.86 | 0.00 | 0.00% | 4.86 | 4.93 | 4.75 |
| Apr 24, 2025 | 5.04 | 0.12 | 2.44% | 4.92 | 5.12 | 4.82 |
| Apr 23, 2025 | 4.96 | 0.04 | 0.81% | 4.92 | 5.19 | 4.88 |
| Apr 22, 2025 | 4.91 | 0.27 | 5.82% | 4.64 | 4.96 | 4.64 |
| Apr 21, 2025 | 4.71 | 0.50 | 11.88% | 4.21 | 4.77 | 4.21 |
| Apr 17, 2025 | 4.37 | 0.32 | 7.90% | 4.05 | 4.39 | 4.05 |
| Apr 16, 2025 | 4.22 | 0.11 | 2.68% | 4.11 | 4.26 | 4.02 |
| Apr 15, 2025 | 4.16 | 0.18 | 4.52% | 3.98 | 4.22 | 3.98 |
| Apr 14, 2025 | 4.01 | 0.23 | 6.08% | 3.78 | 4.05 | 3.73 |
| Apr 11, 2025 | 3.72 | 0.34 | 10.06% | 3.38 | 3.74 | 3.25 |
| Apr 10, 2025 | 3.38 | 0.42 | 14.19% | 2.96 | 3.40 | 2.96 |
| Apr 9, 2025 | 3.09 | 0.14 | 4.75% | 2.95 | 3.35 | 2.92 |
| Apr 8, 2025 | 3.00 | -0.29 | -8.81% | 3.29 | 3.31 | 2.94 |
| Apr 7, 2025 | 3.12 | 0.10 | 3.31% | 3.02 | 3.25 | 2.80 |
| Apr 4, 2025 | 3.20 | 0.03 | 0.95% | 3.17 | 3.30 | 3.15 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Olema Pharmaceuticals, Inc. Company profile
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com